Comments
Biopharmaceutical firm Suven Life Sciences on Thursday said it received grant of five product patents from China and Korea for its new chemical entities for treatment of disorders related to neurodegenerative diseases.
While three of them were from China, two were from Korea, all of which will be valid through 2027 and 2028, respectively, the company said in a statement. With these new patents, Suven now has a total of eight granted patents from China and ten from Korea.
“These patents are exclusive Intellectual Property of Suven and are achieved through the internal discovery research effort. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase- II,” it said.
The company has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development, targeting conditions such as dementia, depression and Parkinson’s disease, in additional a developmental candidate for Alzheimer’s disease and schizophrenia.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.